Medical communications built to survive enforcement review.
The intelligence and production pipeline that turns clinical evidence into compliant, market-legible claims. Every claim connects to the data behind it. Every output reaches human and machine audiences simultaneously.
FDA enforcement didn't tighten incrementally. It shifted.
On September 9, 2025, the FDA announced a crackdown on deceptive drug advertising. What followed was a surge of enforcement action: warning letters and cease-and-desist notices covering channels the agency hadn't cited in years. HCP websites, corporate webpages, influencer content, and earned media placements all drew citations alongside television. CDER issued more than 100 enforcement actions in Q3 2025 alone. Letters now come from CDER Directors, not OPDP staff, and request immediate action.
Most organizations can show the sign-off. They can't produce the evidence chain.
What's missing is the audit trail connecting each approved claim to the specific clinical data that justified it. When the FDA asks about substantiation, most organizations can show the sign-off record. They can't produce the evidence chain.
AI retrieval adds a new layer of exposure. Clinical data processed by AI systems loses its statistical qualifiers, primary endpoint context, and study population specifics. The claim that cleared MLR review arrives at the physician or patient in a form the organization never produced.
From clinical evidence to verified, distributed communications. In hours.
One brief and your source evidence. The system extracts what's worth saying and benchmarks it against the label and the literature. It builds a strategy, produces 19 audience-specific formats, and distributes to human and machine channels in parallel. Every approved claim stays in the ledger. The next piece reuses it instead of re-verifying it, so production speeds up as the ledger grows.
- Extract
- Benchmark
- Plan
- Produce
- Distribute
- Monitor
StoryFlow MedComms produces 19 governed output formats: press releases, disease awareness articles, HCP talking points, investor briefs, video and podcast scripts, and more. Each verified before it ships.
Framework support
Legal guardrails apply throughout the drafting process. Off-label implications, unsupported efficacy claims, and missing safety information are flagged before any human reviewer sees the draft.
Every claim connects to its evidence before it leaves the building.
Attest records every claim, when it was made, and the specific evidence behind it. Each entry seals the one before it. Alter any prior claim and every hash downstream breaks. That record answers OPDP letters, scopes False Claims Act exposure, and settles MLR disputes on demand.
The four-tier ZHTA publish gate checks corpus coverage, evidence cross-validation, cryptographic integrity, and a fair-balance and safety-information scan before any piece ships. Attest records provenance, not truth. Whether your claims are correct remains your organization's call.
Audit-ready claim history for OPDP review, reconstructable on demand.
Per-claim provenance for MLR diligence, traced to the clinical data it rests on.
A tamper-evident record for False Claims Act and off-label exposure.
Inside the organization
Regulatory Affairs
Submissions, labeling, and promotional review draw from one verified evidence base. When OPDP asks for substantiation, the chain from claim to clinical data is already assembled.
Legal & Compliance
Claims arrive with supporting evidence visible from the start. Review shifts from reactive correction to informed confirmation. Language is easier to defend because it has already passed structured verification.
Medical Affairs
Your evidence sets need to travel intact from clinical data to approved messaging. Every paraphrase between the study and the promotional claim is a potential accuracy failure.
Commercial & Brand
Launch messaging moves at market speed without outrunning the evidence. HCP and patient materials stay consistent, on-label, and ready for review.
Early access is limited.
StoryFlow MedComms is in active development. A small cohort of design partners is shaping the first release, defining how the platform handles regulatory frameworks, clinical evidence integration, and MLR workflow support. Direct platform access, structured feedback sessions, and ongoing input into the product roadmap.